The bone marrow (BM) microenvironment, also called the BM niche, is essential for the
maintenance of fully functional blood cell formation (hematopoiesis) throughout life. Under …

The number of HLA-haploidentical hematopoietic cell transplants continues to increase
worldwide due to recent improvements in outcomes, allowing more patients with …

PURPOSE Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during
allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is …

Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly
used to treat hematologic cancers; however, characteristics of the optimal haploidentical …

Allogeneic blood or marrow transplantation (BMT) physicians seek to optimize all possible
variables to improve outcomes. Selectable factors include conditioning, graft-versus-host …

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using
posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a …

Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …

HLA-haploidentical hematopoietic stem cell transplantation is now one of the most
commonly employed alternative donor techniques, with most centers applying T-cell–replete …

Donor selection contributes to improve clinical outcomes of T-cell–replete haploidentical
stem cell transplantation (haplo-SCT) with posttransplant cyclophosphamide (PT-Cy). The …

Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We
compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors …